

Research

Open Access

Role of common human TRIM5 α variants in HIV-1 disease progression

Valérie Goldschmidt^{†1}, Gabriela Bleiber^{†1}, Margaret May², Raquel Martinez¹, Millàn Ortiz¹, Amalio Telenti^{*1} and The Swiss HIV Cohort Study

Address: ¹Institute of Microbiology and University Hospital, University of Lausanne, Switzerland and ²Department of Social Medicine, University of Bristol, UK

Email: Valérie Goldschmidt - Valerie.Goldschmidt@chuv.ch; Gabriela Bleiber - Gabriela.x.Bleiber@gsk.com; Margaret May - M.T.May@bristol.ac.uk; Raquel Martinez - Raquel.Martinez@chuv.ch; Millàn Ortiz - Millan.Ortiz-Serrano@chuv.ch; Amalio Telenti* - Amalio.Telenti@chuv.ch; The Swiss HIV Cohort Study - martin.rickenbach@chuv.ch

* Corresponding author †Equal contributors

Published: 22 August 2006

Received: 10 April 2006

Retrovirology 2006, 3:54 doi:10.1186/1742-4690-3-54

Accepted: 22 August 2006

This article is available from: <http://www.retrovirology.com/content/3/1/54>

© 2006 Goldschmidt et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The retroviral restriction factor tripartite motif protein (TRIM)5 α , is characterized by marked amino acid diversity among primates, including specific clusters of residues under positive selection. The identification of multiple non-synonymous changes in humans suggests that TRIM5 α variants might be relevant to retroviral pathogenesis. Previous studies have shown that such variants are unlikely to modify susceptibility to HIV-1 infection, or the course of early infection. However, the longterm effect of carrying Trim5 α variants on disease progression in individuals infected with HIV-1 has not previously been investigated.

Methods: In a cohort of 979 untreated individuals infected with HIV-1 with median follow up 3.2 years and 9,828 CD4 T cell measurements, we analysed common amino acid variations: H43Y, V112F, R136Q, G249D, and H419Y. The rate of CD4 T cell decline before treatment was used as the phenotype. In addition, we extended previous work on the *in vitro* susceptibility of purified donor CD4 T cells (n = 125) to HIV-1 infection, and on the susceptibility of HeLa cells that were stably transduced with the different TRIM5 variants. Haplotypes were analysed according to the most parsimonious evolutionary structure, where two main human TRIM5 α groups can be defined according to the residue at amino acid 136. Humans present both Q136 and R136 at similar frequency, and additional TRIM5 α amino acid variants are almost exclusively derived from R136-carrying haplotypes.

Results: We observed modest differences in disease progression for evolutionary branches carrying R136-derived haplotypes, and with the non-synonymous polymorphisms G249D and H419Y. *In vitro* analysis of susceptibility of donor CD4 T cells, and of the various transduced HeLa cell lines supported the absence of significant differential restriction of HIV-1 infection by the various huTRIM5 α alleles.

Conclusion: Common human variants of TRIM5 α have no effect or modest effect on HIV-1 disease progression. These variants occur at sites conserved throughout evolution, and are remote from clusters of positive selection in the primate lineage. The evolutionary value of the substitutions remains unclear.

Background

The tripartite motif (TRIM) family is a well conserved family of proteins characterized by a structure comprising a RING domain, one or two B-boxes and a predicted coiled-coil region [1]. In addition, most TRIM proteins have additional C-terminal domains. Members of the TRIM protein family are involved in various cellular processes, including cell proliferation, differentiation, development, oncogenesis and apoptosis (for recent review [2,3]). Some TRIM proteins display antiviral properties, targeting retroviruses in particular [4].

TRIM5 α is a retroviral restriction factor targeting the early steps of cellular infection [4]. TRIM5 α restricts retroviral infection by specifically recognizing the capsid and promotes its premature disassembly [5]. Human TRIM5 α (huTRIM5 α) has limited efficacy against HIV-1, while some primate TRIM5 α orthologues can potently restrict this particular lentivirus (for review see [2,3]). Considerable inter-species sequence diversity characterizes TRIM5 α and might underlie differences in the pattern and breadth of restriction of multiple lentiviruses. Evolutionary analysis reveals that up to 2% of codons of TRIM5 α are predicted to be under positive selection with high confidence [6,7]. Residues under positive selection cluster in the C-terminal B30.2 domain. A first cluster resides between amino acids 322 to 340 in the variable region v1 [7,8], a region previously described as a "patch" of positive selection [6]. Replacement of the v1 region, or of specific amino acids within v1, modifies the restriction pattern of TRIM5 α [9,10]. The second cluster, localized between amino acids 381 to 389 [7], corresponds to the previously described variable region v2 of the B30.2 domain [8]. Substitution of the human v2 region by a v2 from Rhesus monkeys exhibits no inhibitory activity against HIV-1 [9,10]. However, v2 variants are thought to result in species-specific lentiviral restriction patterns [11]. An additional region of considerable variation among Sooty mangabeys and Rhesus monkeys has been mapped to the coiled-coil motif [12].

Recently, two studies have addressed the potential role of huTRIM5 α variants in modulating susceptibility to HIV-1 [13,14]. Sawyer et al. identified several non-synonymous SNPs in huTRIM5 α , but only one of these (H43Y) was found to have a functional consequence [13]. H43Y lies in the RING domain of TRIM5 α and may negatively affect its putative E3 ubiquitin ligase activity. Although huTRIM5 α weakly restricts HIV-1, H43Y might further reduce viral restriction to a level similar to that of cells expressing no exogenous huTRIM5 α [13]. To assess whether the impaired retroviral restriction seen with exogenously expressed huTRIM5 α H43Y resulted in altered susceptibility in human cells, Sawyer et al. tested B-lymphocytes from four individuals: one homozygous for H43, two

homozygous for 43Y, and one heterozygous at this residue. Challenge with HIV-1 failed to demonstrate a significant effect of the H43Y change, although 43Y homozygous cells could be infected with N-MLV about 100-fold more efficiently than cells with the common H43 allele [13]. In a second study, Speelman et al. assessed the association of various non-synonymous variants with susceptibility to HIV-1 among 110 HIV-1 infected subjects and 96 exposed seronegative persons [14]. This study identified possible associations between specific haplotypes and alleles and susceptibility to infection and viral setpoint after acute infection.

In our study, we analysed data from a large cohort of subjects infected with HIV-1 to explore whether different huTRIM5 α variants are associated with long-term disease evolution. The study is complemented by analysis of CD4 cell susceptibility to HIV-1, and the *in vitro* functionality of selected huTRIM5 α variants. We conclude from our study that there is no impact for some and negligible to modest impact for other common human variants of TRIM5 α on disease progression.

Results and discussion

TRIM5 α polymorphism

TRIM5 α is characterized by important sequence diversity in humans, as shown in this and in previous studies [13,14]. Analysis of huTRIM5 α polymorphism in blood donors identified 21 genetic variants (Additional file 1), including four SNPs leading to non-synonymous changes: 127C>T (rs3740996, H43Y, allelic frequency $f = 0.11$), 407G>A (rs10838525, R136Q, $f = 0.35$), 12468G>A (rs11038628, G249D, $f = 0.08$), and 15142C>T (rs28381981, H419Y, $f = 0.05$). One additional common variant (rs11601507, V112F, $f = 0.08$), and several rare non-synonymous variants have been described in the other studies [13,14]. Changes involve evolutionary conserved positions (Figure 1). None of these changes are within patches of positive selection in primates, in particular none are in the proximity of variable regions v1 and v2 of the B30.2 domain (Figure 1), and thus their evolutionary significance is uncertain. We speculate that R136Q might result from balancing selection because humans carry Q136, the ancestral amino acid, and R136, an amino acid shared only with chimpanzees, with similar frequencies.

Association of genetic variants with *in vitro* susceptibility to infection

Data from Sawyer et al. indicated that H43Y results in reduced capacity to restrict N-MLV, but has minimal or no impact on HIV-1 susceptibility to infection *in vitro* in feline fibroblasts (CRFK) cells [13]. We extend and confirm these results by showing that HeLa cells stably transfected with the different human variants of TRIM5 do not




Figure 1
Position of common human TRIM5 α amino acid variants in the context of primate sequence conservation and of the v1 and v2 patches of positive pressure. Y-axis: posterior probabilities of positively selected codons. X-axis: human TRIM5 α amino acid numbering. The evolutionary analysis is adapted from reference [7].

differ in susceptibility to HIV-1 infection (Figure 2). We also confirmed that the H43Y variant failed to restrict N-MLV in the HeLa background (Additional file 2). Thus, results in HeLa cells, that express TRIM5 α endogenously, are in full concordance with data from CRFK cells. HeLa cells have the most common TRIM5 alleles (-2CC, H43, V112, heterozygous R136Q, G249, H419).

Speelmon et al. [14] reported on the permissiveness of purified CD4 T cells from 77 seronegative donors. Analysis included assessment of H43Y, R136Q, H419Y, and a series of less common variants. We performed similar experiments by infecting purified CD4 T cells from 125 Caucasian healthy blood donors with replicating HIV-1. Alleles tested included H43Y, R136Q, H419Y, and the common variant G249D (not tested in the above study). There was no significant association of specific variants or haplotypes with *in vitro* p24 production after 7 days

(Additional file 3). None of the additional SNPs investigated *in vitro* were associated with differences in cell permissiveness (Additional file 1).

Association of genetic variants with disease progression in vivo

The reports by Sawyer et al and Speelmon et al. [13,14] suggested that some of the alleles could indeed have an impact on HIV-1 susceptibility *in vivo*. We extended their analyses by investigating the association of the various huTRIM5 α variants with long-term disease progression in a large cohort of individuals infected with HIV-1. The clinical phenotype was defined as the patient-specific rate of CD4 T cell decline, a recognized marker of disease progression [15]. Analysis excluded any CD4 T cell values after initiation of treatment. The median follow up time was 3.2 years, during which 979 cohort participants, not receiving antiretroviral treatment, contributed 9,828 CD4




Figure 2
Restriction of HIV-1 by common human TRIM5 α variants. HeLa cells were stably transduced by oncoretroviral vectors expressing the Rhesus (Rh) TRIM5 α , the common huTRIM5 α and its variants, separately or in a hypothetical four-mutation protein. Panel A: Single-cycle infectivity assays used VSV-pseudotyped recombinant viruses (HIV-1-GFP) at various m.o.i. After 48 h, cells were analysed by fluorescence-activated cell sorter, and scored for number of GFP-positive cells. Panel B: Expression of HA-tagged TRIM5 α proteins was determined by western blotting using an anti-HA antibody. Tubulin was detected with the anti- α tubulin antibody. Control: HeLa cells transduced with an empty oncoretroviral vector.

T cell determinations to the analysis (median 7 CD4 T cell determinations per participant). We first tested for associations of individual non-synonymous polymorphisms with differences in the natural history of disease progression. H43Y and R136Q had no effect on disease progression. Participants who had one or two copies of G249D or H419Y had slower progression although confidence intervals were wide due to small numbers. Compared to non-carriers who had a square root transformed CD4 gradient of -2.02, participants who were carriers of G249D and H419Y had gradients of -1.74 (95% CI -1.39 to -2.09, $p = 0.11$) and -1.64 (95% CI -1.33 to -1.95, $p = 0.02$) respectively.

Haplotypes were assessed according to the most parsimonious evolutionary analysis, where two main huTRIM5 α groups can be defined according to the residue at amino

acid 136 (Figure 3). With the notable exception of chimpanzees and humans that carry an arginine at position 136, all other primates code for a glutamine at codon 136 (glutamic in tamarins), which therefore represents the ancestral sequence for old world monkeys, gibbons and apes. However, humans have similar frequencies of Q136 and R136, and additional TRIM5 α amino acid variants are almost exclusively derived from R136-carrying haplotypes (data from this study and from [14]). We did not observe differences in HIV-1 disease progression for evolutionary branches carrying Q136- or R136-containing haplotypes (Figure 3). Weak associations of some haplotypes with disease progression were found, but the p values did not reach the experiment wide corrected significance level of $p = 0.0028$ (Simes modified Bonferroni p value).

Whilst our study was being completed, Sawyer et al. [13] and Speelman et al [14] reported on an additional common variant V112F (allelic frequency of 7%). We re-genotyped the cohort and identified the presence of 112F in R136-carrying haplotypes. We confirm the absence of significant effect of this particular amino acid on disease progression [CD4 T cell gradient: -2.21 (95% CI -1.89 to -2.534) compared to mean reference slope -2.01]. In addition, Speelman et al. included in their analysis the 5'UTR -2C>G SNP [14]. The -2C represents the ancestral allele and is present in high linkage disequilibrium with Q136. Speelman et al. identified a rare haplotype, where individuals carried -2G in the context of Q136, possibly associated with susceptibility to HIV infection (OR 5.49, $p = 0.02$) [14]. We also identified this rare haplotype (frequency of 1.4%), but did not observe any association with disease progression [CD4 T cell gradient: -2.04 (95% CI -1.20 to -2.88)].

Conclusion

We have extended previously reported findings on huTRIM5 α by showing that the amino acid variant H43Y which results in loss of restriction of N-MLV [13] is not associated with significant differences in HIV-1 disease progression in a large human cohort. The present study also underscores the modest or negligible effect of human variants G249D and H419Y and of some haplotypes on HIV-1 susceptibility and disease progression. Despite the conserved nature of these residues in primates, the evolutionary relevance of the variants in humans is uncertain. However, it is possible that the polymorphisms found in TRIM5 α might have been selected in past epidemics by viruses unrelated to HIV-1.

Materials and methods

Cells

CD4 T cells from 125 healthy Caucasian blood donors were isolated by anti-CD4 magnetic beads (Miltenyi Biotech) and cultured *ex vivo* in RPMI-1640 (Gibco-Invitro-

A

Haplotype	127C>T	407G>A	12468G>A	15142C>T	Haplotype Frequency
H1	C	G	G	C	0.45
H2	C	G	G	T	0.01
H3	C	G	A	C	0.08
H4	C	A	G	C	0.34
H5	C	A	G	T	<0.01
H6	C	A	A	C	<0.01
H7	T	G	G	C	0.07
H8	T	G	G	T	0.04
H9	T	G	A	C	<0.01
H10	T	A	G	C	<0.01
Allele Frequency	0.11	0.35	0.08	0.05	
Aminoacid change	H43Y	R136Q	G249D	H419Y	

B




Figure 3

Association of human TRIM5α haplotypes with HIV-1 disease progression *in vivo*. Panel A, Inferred haplotypes carrying non-synonymous variants. Panel B, Analysis of haplotypes according to the most parsimonious evolutionary analysis, where two main huTRIM5α groups can be defined according to the residue at codon 136. Shown are square root CD4 gradient (reference slope for all patients is -2.01). Top set of slope estimates corresponds to one copy of haplotype(s) group, bottom set is for two copies of haplotype(s) group. Only the H7 haplotype presented a slope significantly different from that of all patients (uncorrected p value). However, p values did not reach the experiment-wide significance of 0.003 (Simes modified Bonferroni p value).

gen), supplemented with 20% fetal calf serum (FCS), 20 U/ml human IL-2 (Roche) and 50 µg/ml gentamicin, following stimulation with 2 µg/ml phytohaemagglutinin (PHA) during two days. CD4 T cells (10⁶ cells) were infected with R5 clone HIV-1 NL4-3BaLenv (1000 pg p24 antigen) for 2 hours at 37°C, 5% CO₂, in 1 ml final volume. Cells were washed and cultured for 7 days. Virus-containing supernatant was harvested and p24 antigen production was monitored by ELISA (Abbott). Permissiveness was defined as the ability of cells to be infected

and sustain replication of HIV-1 [16]. The *ex vivo* viral replication for each genotype was represented by the median p24 antigen production at day 7.

Identification of SNPs, and allelic discrimination

Single nucleotide polymorphism (SNP) discovery used single strand conformation polymorphism and sequencing of 94 chromosomes (47 Caucasian blood donors). For this, a total of 21 PCR reactions were designed to cover exons, putative promoter regions, and intron-exon

boundaries (6771 bp/subject). SNPs resulting in non-synonymous substitutions were then genotyped by using TaqMan allelic discrimination (Additional file 4).

Biological analysis of huTRIM5 α variants

The pLPCX oncoretroviral vector containing the human and Rhesus TRIM5 α gene with an HA epitope tag was obtained from the NIH AIDS Reagent Program (donated by J. Sodroski). Variants of huTRIM5 α were made by using the QuikChange protocol (Stratagene). Retroviral vectors were packaged by co-transfecting the various pLPCX constructs with the pNB-tropic MLV Gag-Pol and pVSV-G packaging plasmids [17]. Supernatants were concentrated and used to transduce HeLa cells. Seventy two hours after transduction, cells were selected in 0.5 mg/ml puromycin. Expression of HA-tagged TRIM5 α proteins were determined by Western blotting using an anti-HA antibody (Roche). Tubulin was detected with the anti- α tubulin antibody (Sigma). Single-cycle infectivity assays in HeLa cells used the VSV-pseudotyped recombinant viruses HIV.1-GFP and N-MLV-GFP at various m.o.i. Cells were analysed by fluorescence-activated cell sorter (FACS) 48 h after transduction.

In vivo analysis: CD4 cell count decline

Study participants (n = 979) were recruited within the genetics project of the Swiss HIV Cohort Study [18]. The ethics committees of all participant centers approved the study. Patients gave written informed consent for genetic testing. DNA from PBMCs was used for genotyping. Their characteristics are shown in Additional file 5. The rate of decline in CD4 T cell count during the natural history of disease progression was defined as study phenotype as previously reported [19]. The CD4 T cell trajectories were modeled using a repeated measures hierarchical approach using Mlwin software [20]. Square root transformed CD4 T cell counts were modeled as a linear function of time since estimated date of seroconversion with random effects for both the intercept and the gradient with additional terms for sex, age, and risk group [19]. For each genotype, the average square root CD4 decline per year was estimated in dominant and recessive models. Haplotypes were attributed using PHASE [21].

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

VG and GB carried out re-sequencing, genotyping studies, and construction of expression vectors. VG performed the transduction assays. MM did statistical analyses, data modeling and revised the manuscript. RM did SNP discovery and genotyping studies. MO performed the bioinformatics analyses. AT conceived the study, supervised the

molecular genetic analysis, secured funding, and drafted the manuscript.

Additional material

Additional file 1

Genetic variants and their association with HIV-1 cell permissiveness in vitro in purified CD4 T cells from 125 healthy blood donors.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1742-4690-3-54-S1.pdf>]

Additional file 2

Restriction of N-MLV by common human TRIM5 α variants.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1742-4690-3-54-S2.pdf>]

Additional file 3

Analysis of association of specific human TRIM5 α variants or haplotypes and in vitro p24 production 7 days post infection of purified CD4 T cells from healthy blood donors with an R5-tropic viral strain.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1742-4690-3-54-S3.pdf>]

Additional file 4

TaqMan allelic discrimination primers and probes.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1742-4690-3-54-S4.pdf>]

Additional file 5

Characteristics of 979 subjects infected with HIV-1.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1742-4690-3-54-S5.pdf>]

Acknowledgements

This study has been financed in the framework of the Swiss HIV Cohort Study, supported by the Swiss National Science Foundation. (Grant no 3345-062041), and by Swiss National Science Foundation grant no. 310000-110012/1 to A.T.

The members of the Swiss HIV Cohort Study are S. Bachmann, M. Battegay, E. Bernasconi, H. Bucher, Ph. Bürgisser, M. Egger, P. Erb, W. Fierz, M. Fischer, M. Flepp (Chairman of the Clinical and Laboratory Committee), P. Francioli (President of the SHCS, Centre Hospitalier Universitaire Vaudois, CH-1011 - Lausanne), H.J. Furrer, M. Gorgievski, H. Günthard, P. Grob, B. Hirschel, L. Kaiser, C. Kind, Th. Klimkait, B. Ledergerber, U. Lauper, M. Opravil, F. Paccaud, G. Pantaleo, L. Perrin, J.-C. Piffaretti, M. Rickenbach (Head of Data Center), C. Rudin (Chairman of the Mother & Child Study), J. Schupbach, R. Speck, A. Telenti, A. Trkola, P. Vernazza (Chairman of the Scientific Board), R. Weber, S. Yerly.

References

1. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, Guffanti A, Minucci S, Pelicci PG,

- Ballabio A: **The tripartite motif family identifies cell compartments.** *EMBO J* 2001, **20**:2140-2151.
2. Nisole S, Stoye JP, Saib A: **TRIM family proteins: retroviral restriction and antiviral defence.** *Nat Rev Microbiol* 2005, **3**:799-808.
 3. Towers GJ: **Restriction of retroviruses by TRIM5 alpha.** *Future Virol* 2006, **1**:71-78.
 4. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J: **The cytoplasmic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys.** *Nature* 2004, **427**:848-853.
 5. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, az-Griffero F, Anderson DJ, Sundquist VI, Sodroski J: **Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor.** *Proc Natl Acad Sci U S A* 2006, **103**:5514-5519.
 6. Sawyer SL, Wu LI, Emerman M, Malik HS: **Positive selection of primate TRIM5{alpha} identifies a critical species-specific retroviral restriction domain.** *Proc Natl Acad Sci U S A* 2005, **102**:2832-2837.
 7. Ortiz M, Bleiber G, Martinez R, Kaessmann H, Telenti A: **Patterns of evolution of host proteins involved in retroviral pathogenesis.** *Retrovirology* 2006, **3**:11.
 8. Song B, Gold B, O'Huigin C, Javanbakht H, Li X, Stremlau M, Winkler C, Dean M, Sodroski J: **The B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates.** *J Virol* 2005, **79**:6111-6121.
 9. Stremlau M, Perron M, Welikala S, Sodroski J: **Species-Specific Variation in the B30.2(SPRY) Domain of TRIM5{alpha} Determines the Potency of Human Immunodeficiency Virus Restriction.** *J Virol* 2005, **79**:3139-3145.
 10. Yap MW, Nisole S, Stoye JP: **A Single Amino Acid Change in the SPRY Domain of Human Trim5alpha Leads to HIV-1 Restriction.** *Curr Biol* 2005, **15**:73-78.
 11. Stoye JP: **Restriction of retrovirus replication.** *13th Conference on Retroviruses and Opportunistic Infections, Denver 2006-Abstract 59.*
 12. Newman R, Hall L, Connole M, Chen GL, Kaur A, Miller G, Johnson W: **Balancing selection, gene duplication and functional polymorphism in the Rhesus macaque and Sooty mangabey TRIM5alpha locus.** *13th Conference on Retroviruses and Opportunistic Infections, Denver 2006-Abstract 141LB.*
 13. Sawyer SL, Wu LI, Akey JM, Emerman M, Malik HS: **High-Frequency Persistence of an Impaired Allele of the Retroviral Defense Gene TRIM5alpha in Humans.** *Curr Biol* 2006, **16**:95-100.
 14. Speelman EC, Livingston-Rosanoff D, Li SS, Vu Q, Bui J, Geraghty DE, Zhao LP, McElrath MJ: **Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection.** *J Virol* 2006, **80**:2463-2471.
 15. Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA: **Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.** *JAMA* 2000, **283**:381-390.
 16. Williams LM, Cloyd MW: **Polymorphic human gene(s) determines differential susceptibility of CD4 lymphocytes to infection by certain HIV-1 isolates.** *Virology* 1991, **184**:723-728.
 17. **Didier Trono laboratory** 2006 [<http://tronolab.epfl.ch>].
 18. **The Swiss HIV Cohort Study** 2006 [<http://www.shcs.ch/>].
 19. Bleiber G, May M, Martinez R, Meylan P, Ott J, Beckmann J, Telenti A: **Use of a combined ex vivo/in vivo population approach for screening of human genes involved in the Human immunodeficiency virus type 1 life cycle for variants influencing disease progression.** *J Virol* 2005, **79**:12674-12680.
 20. **MLwiN: a visual interface for multilevel modelling** 2006 [<http://www.mlwin.com/>].
 21. **PHASE: software for haplotype reconstruction, and recombination rate estimation from population data** 2006 [<http://www.stat.washington.edu/stephens/software.html>].

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

